Evaluation of T-helper 22 and T-helper17 in patients with breast cancer
DOI:
https://doi.org/10.36320/ajb/v8.i3.9301Keywords:
Breast cancer, Th17 ,IL-17A , TNF-α and AP-1 GenesAbstract
The interplay between Th-17 and Th-22 cells plays vital role in tumor immunity . Therefore, this study aimed to focus on these cells in patients with breast cancer. The results of this study showed that there were a highly significant increment in concentrations of IL-17A(139.5±17pg/ml) compared with control group which was (41.33±11.3pg/ml) and showed results were a highly significant elevation in concentration of IL-23P19 (192.73±22.3pg/ml) while control group was (121.41±14.7pg/ml). Also The results showed a highly significant increment in concentration of IL-22 (137.25±24.6pg/ml) compared to control group which was (77.67±13.7pg/ml) and also in TNF-α concentration was (200±23.7pg/ml) compared with control group which was (10.5±7.3pg/ml). Molecular findings recorded a significant elevation in the levels of AP-1 gene expression were Fos 18.76±7.8 in patients group and 9.05±1.12 control group, also the values of JunD gene 15.77±9.43 and 6.18±0.112, and lastly JunB 23.223±11.34 in comparison to control group7.33±3.76.Overall findings revealed considerable inflammatory response by Th-17 and Th-22 and remarkable AP-1 gene expression.
Downloads
References
-Jemal A., Center M.M., DeSantis C., and Ward E. M.(2010).Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev; 19: 1893 – 1907. DOI: https://doi.org/10.1158/1055-9965.EPI-10-0437
-Gray J., Evans N., Taylor B., Rizzo J., Walker M. (2009)State of the evidence: the connection between breast cancer and the environment. Int J Occup Environ Health. 15: 43-78. DOI: https://doi.org/10.1179/oeh.2009.15.1.43
-Jemal A., Bray F., Center M.M., Ferlay J., Ward E. and Forman D.(2011) Global cancer statistics. CA Cancer J Clin. 61(2):69–90. DOI: https://doi.org/10.3322/caac.20107
-American Cancer Society. Global cancer facts and figures, 2nd ed., Atlanta: ACS, (2011).
-Ferlay J., Shin H., Bray F., Forman D., Mathers C.and Parkin D.M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127(12):2893-917. DOI: https://doi.org/10.1002/ijc.25516
-Ahmad O., Boschi-Pinto C., Lopez A., Murray C., Lozano R., Inoue M. (2001) .Age standardization of rates: a new WHO standard. GPE Discussion Paper Series No. 31. Geneva: World Health Organization.
-Parkin D.M., Bray F., Ferlay J.and Pisani P. (2005).Global cancer statistics, 2002. CA Cancer J Clin. 55(2):74–108. DOI: https://doi.org/10.3322/canjclin.55.2.74
-DeNardo D.G.& Coussens L.M.( 2007) .Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res.;9(4):212. DOI: https://doi.org/10.1186/bcr1746
-Pierce B.L., Ballard-Barbash R., Bernstein L., Baumgartner R.N., Neuhouser M.L., Wener M.H, Gilliland F.D., Baumgartner K.B., Sorensen B., McTiernan A. and Ulrich C.M. ( 2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol.;27(21):3437-44. DOI: https://doi.org/10.1200/JCO.2008.18.9068
-Rao V.S., Dyer C.E., Jameel J.K., Drew P.J.and Greenman J. (2006)Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep.;15(1):179-85. DOI: https://doi.org/10.3892/or.15.1.179
-Esquivel-Velazquez M., Ostoa-Saloma P., Palacios- Arreola M.I., Nava-Castro K.E., Castro J.I. and Morales-Montor J.( 2015) The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res.;35(1):1-16. DOI: https://doi.org/10.1089/jir.2014.0026
-Annunziato F.& Romagnani S.(2009) Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther; 11: 257. DOI: https://doi.org/10.1186/ar2843
-Zhu J.& Paul W.E.(2010) . Heterogeneity and plasticity of T helper cells. Cell Res; 20: 4 – 12. DOI: https://doi.org/10.1038/cr.2009.138
-Weaver C.T.& Hatton R.D.(2009)Interplay between the TH17 and Treg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol; 9: 883 – 889. DOI: https://doi.org/10.1038/nri2660
- Alqassemi, Z.A.; Alkhozai, Z.M.(2016). Immune Modulation in Patient with Varicella Zoster Virus Treated with Phototherapy and Chemotherapy.J.ARC Dermatol. Vol.1, Issue 1, PP 1-9. DOI: https://doi.org/10.20431/2456-0022.0101001
-Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., Dong C.(2005) .A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6:1133-1141. DOI: https://doi.org/10.1038/ni1261
-Dong C. (2008).TH17 cells in development : an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8(5):337–48. DOI: https://doi.org/10.1038/nri2295
-Bettelli E., Korn T.and Kuchroo V.K.(2007) Th17: the third member of the effector T cell trilogy. Curr Opin Immunol, 19:652e657 DOI: https://doi.org/10.1016/j.coi.2007.07.020
-Zheng, Y., Danilenko, D. M., Valdez, P. , Kasman I, Eastham-Anderson J, Wu J, Ouyang W. (2007). Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445(7128):648-51. DOI: https://doi.org/10.1038/nature05505
-Veldhoen, M., Hirota, K., Christensen, J., O’Garra, A. and Stockinger, B. (2009). Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J. Exp. Med. 206:43. DOI: https://doi.org/10.1084/jem.20081438
-Balkwill F. (2009). Tumor necrosis factor and cancer. Nat Rev Cancer 9:361–371 DOI: https://doi.org/10.1038/nrc2628
-Daschner,P.J.; Ciolino, H.P.; Plouzek, C.A. and Yeh, G.C.(1999).Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells.Breast Cancer Res.and Treat.53:229-240. DOI: https://doi.org/10.1023/A:1006138803392
-Zhao,C.; Qiao,Y.; Jnsson,P.; Wang, J.; Xu,L.;Rouhi,P.;Sinha,I.;Cao,Y.;Williams,C.;Wright,K.D.(2014).Genome-wide profiling of AP-1 regulated transcription provides insights into the invasiveness of triple-negative breast cancer. Cancer Res.15:74(14)3983-3994. DOI: https://doi.org/10.1158/0008-5472.CAN-13-3396
-Bamberger,A.M.;Methner,C.;Lisboa,B.W.;Stadtler, C.; Schulte, H.M.; Loning, T. and Langosch, K.M.(1999).Expression pattern of the AP-1family in breast cancer association of fosB expression with a well-Differentiated receptor-positive tumor phenotype. Int. J. Cancer(Pred. oncol.)84,533-538. DOI: https://doi.org/10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J
- Hayase, H.; Ishizu ,A.; Ikeda ,H.; Miyatake, Y.; Baba, T.; Higuchi, M , and et al. (2005). Aberrant gene expression by CD25+CD4+ immune-oregulatory T cells in autoimmune-prone rats carrying the human T cell leukemia virus type-I gene. The Japanese Society for Immunology 17:677–684. DOI: https://doi.org/10.1093/intimm/dxh238
- Wang ,G .and Hardy ,M.P. (2004). Development of leydig cells in the insulin-ike growth factor-I (igf-I) knockout mouse: effects of igf-I replacement and gonadotropic stimulation. Biol Reprod. 70:632–639. DOI: https://doi.org/10.1095/biolreprod.103.022590
- McDonald, J.H. (2009). Handbook of Biological Statistics. 2nd ed., Sparky House Publishing, Baltimore, Maryland.
- Ji Y., Zhang W. (2010).Th17 cells: positive or negative role in tumor? Cancer Immunol. Immunother.; 59: 979-87. DOI: https://doi.org/10.1007/s00262-010-0849-6
-Zheng J. , Jiang L., Zhang L., Yang L., Deng J., You Y., Li N., Wu H., Li W., Lu J. and Zhou Y. (2012) Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations. Carcinogenesis 2409-2416, DOI: https://doi.org/10.1093/carcin/bgs307
- Sugita,S.; Kawazoe, Y.;Imai, A.; Usui, Y.Takashi, M. and Mochizuki, M.(2013). Suppression of IL-22 producing Helper 22 cells by RPE cells via PD-Li/PD-1 interactions. Investigative .Ophthalmol. and Visual Sci.54,6926-6933. DOI: https://doi.org/10.1167/iovs.13-12703
-Kim K., Kim G., Kim J.Y., Yun H.J., Lim S.C. and Choi H.S.(2014).Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation Available from: Carcinogenesis. 35(6):1352-61. DOI: https://doi.org/10.1093/carcin/bgu044
-Bailey S.R., Nelson M.H., Himes R.A., Li Z., Mehrotra S. and Paulos C.M. (2014). Th17 cells in cancer: the ultimate identity crisis. Front. Immunol. 5:276. DOI: https://doi.org/10.3389/fimmu.2014.00276
- Iwakura Y., Ishigame H., Saijo S. and Nakae, S. (2011) .Functional specialization of interleukin-17 family members, Immunity, 34( 2). 149–162. DOI: https://doi.org/10.1016/j.immuni.2011.02.012
-Knower K. C., To S. Q. G., Cheung V., Lazarus K. A. and Clyne C. D. (2014) . Origins and Actions of TNF-Alpha in the Breast Tumor Microenvironment: A Novel Model of Targeted Inhibition through Endocrine Therapy .Endocrine Society's 96th Annual Meeting and Expo, June 21–24, Chicago -
-Wilson, N. J., Boniface, K., Chan, J. R., McKenzie B.S., Blumenschein W.M., Mattson J.D., Basham B., Smith K., Chen T., Morel F., Lecron J.C., Kastelein R.A., Cua D.J., McClanahan T.K., Bowman E.P., de Waal Malefyt R.(2007). Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8:950. DOI: https://doi.org/10.1038/ni1497
-Sankpal,N.V.; Mayfield, J.D.; William, M.W.; Fleming, T.P. and Gillanders,W. (2011).Activator protein 1(AP1) contribute to EpCAM dependent breast cancer invasion.Breast Cancer Res. 13,R124,1-13. DOI: https://doi.org/10.1186/bcr3070
-Fu,J.; Cheng,L.; Wang, Y.; Yuan, P.; Xu, X.; Ding, L.; Zhang, H.; Jiang, K.; Song, H.; Chen, Z. and Ye, Q.(2015).The RNA-binding protein RBPMS1 represses AP-1 signaling and regulates breast cancer cell proliferation and migration. Biochem. Et.Biophysic.Acta.1853.1-13. DOI: https://doi.org/10.1016/j.bbamcr.2014.09.022
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Dina M.R. Alkhafaf, Raghda S. M. AlOmari, Ziad M. Alkhozai
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
